|
Male gender, n (%)
|
87 (64.4)
|
41 (74.5)
|
0.23
|
|
Age (year), median (IQR)
|
59.2 (52.2–65.8)
|
60.4 (50.2–67.1)
|
0.99
|
|
Cancer type
| | |
0.39
|
|
Haematological malignancy, n (%)
|
95 (70.4)
|
35 (63.6)
| |
|
Solid tumour, n (%)
|
40 (29.6)
|
20 (36.4)
| |
|
Cancer stage
| | |
0.91
|
|
Diagnosis, n (%)
|
36 (26.7)
|
15 (27.3)
| |
|
Complete remission, n (%)
|
29 (21.5)
|
13 (23.6)
| |
|
Partial remission, n (%)
|
31 (23)
|
14 (25.5)
| |
|
Evolutive, n (%)
|
39 (28.9)
|
13 (23.6)
| |
|
HSCT, n (%)
|
47 (24.7)
|
14 (25.4)
|
0.43
|
|
Admission purpose
| | |
0.32
|
|
Septic shock, n (%)
|
59 (43.7)
|
21 (38.2)
| |
|
Acute respiratory failure, n (%)
|
51 (37.8)
|
27 (49.1)
| |
|
Coma, n (%)
|
14 (10.4)
|
2 (3.6)
| |
|
Others, n (%)
|
11 (8.1)
|
5 (9.1)
| |
|
Clinical sepsis upon admission
| | |
0.042
|
|
Respiratory, n (%)
|
79 (58.5)
|
31 (56.4)
| |
|
Non-respiratory, n (%)
|
31 (23)
|
6 (10.9)
| |
|
None, n (%)
|
25 (18.5)
|
18 (32.7)
| |
|
Characteristics upon admission
| | | |
|
Neutropenia, n (%)
|
54 (40)
|
18 (32.7)
|
0.41
|
|
Antibiotherapy, n (%)
|
104 (77)
|
43 (78.2)
|
1
|
|
Corticosteroids (curative), n (%)
|
32 (23.7)
|
19 (34.5)
|
0.15
|
|
SOFA score (day of intubation), median (IQR)
|
11 (8–14)
|
11 (8–13)
|
0.28
|
|
Characteristics at the first 48 h of MV
| | | |
|
Vasopressors, n (%)
|
99 (73.3)
|
44 (80)
|
0.36
|
|
Renal replacement therapy, n (%)
|
28 (20.7)
|
9 (16.4)
|
0.55
|
|
Substitutive hydrocortisone, n (%)
|
96 (71.1)
|
26 (47.3)
|
0.003
|
|
G-CSF, n (%)
|
20 (14.8)
|
9 (16.4)
|
0.82
|
|
Enteral nutrition, n (%)
|
40 (29.6)
|
21 (38.2)
|
0.3
|
|
Antibiotherapy
| | |
0.09
|
|
Adapted, n (%)
|
41 (30.4)
|
11 (20)
| |
|
Empirical, n (%)
|
89 (65.9)
|
38 (69)
| |
|
None, n (%)
|
5 (3.7)
|
6 (10.7)
| |
